Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 11:43 AM ET


Company Overview of Agios Pharmaceuticals, Inc.

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK...

38 Sidney Street

2nd Floor

Cambridge, MA 02139

United States

Founded in 2007

128 Employees



Key Executives for Agios Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 58
Total Annual Compensation: $500.0K
Principal Financial Officer and Senior Vice President of Finance
Age: 44
Total Annual Compensation: $309.0K
Chief Medical Officer
Age: 54
Total Annual Compensation: $371.4K
Chief Scientific Officer
Age: 59
Total Annual Compensation: $387.3K
Compensation as of Fiscal Year 2014.

Agios Pharmaceuticals, Inc. Key Developments

Agios Pharmaceuticals, Inc. Appoints Steve Hoerter as Chief Commercial Officer, Effective February 16, 2016

Agios Pharmaceuticals, Inc. announced the appointment of Steve Hoerter to the newly created position of chief commercial officer, effective February 16, 2016. Mr. Hoerter has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served as executive vice president and chief commercial officer at Clovis Oncology, Inc. as well as previous senior commercial roles at Genentech and Roche.

Perry Karsen to Resign from the Board of Directors of Agios Pharmaceuticals, Inc., Effective March 1, 2016

On February 1, 2016, Perry Karsen notified Agios Pharmaceuticals, Inc. of his decision to resign from the board of directors of the company, effective March 1, 2016.

Agios Pharmaceuticals, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:30 AM

Agios Pharmaceuticals, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:30 AM. Venue: The Waldorf Astoria, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Alzheon, Inc. United States
Kineta Three, LLC United States
IsoTis, Inc. United States
Adjuvance Technologies, Inc. United States
Nurel Therapeutics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Agios Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at